Results 81 to 90 of about 1,741 (166)

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort. [PDF]

J Pers Med
Nicola S, Negrini S, Ribolla F, Guida G, Rinaldo RF, Bondi B, Badiu I, Corradi F, Quinternetto A, Vitali I, Lo Sardo L, Crida B, Mhimid L, Tocci SL, Teocchi M, Milione A, Marengo M, Heffler E, Canonica GW, Blasi F, Paggiaro P, Boem M, Basiglio S, Alessi L, Braido F, Ricciardolo FLM, Solidoro P, Bagnasco D, Brussino L, On Behalf Of The Sani Study Group.   +29 more
europepmc   +1 more source

Influence of PAI-1 gene polymorphism on the effectiveness of tezepelumab in individuals with severe asthma: a study protocol for a prospective, non-randomized, interventional, comparative trial. [PDF]

J Thorac Dis
Fukahori S, Obase Y, Fukushima C, Kosai K, Yanagihara K, Hara S, Tomari S, Tsubouchi H, Miyazaki T, Matsuo N, Matsuo A, Matsumoto N, Ide H, Tobino K, Kodaka N, Matsuse H, Arakaki W, Haranaga S, Yamamoto K, Yoshimine H, Sakakibara H, Yatera K, Tashiro H, Takahashi K, Himeji D, Mukae H.   +25 more
europepmc   +1 more source

Clinical Benefits of Tezepelumab in a Real-World Cohort of Patients With Severe Uncontrolled Asthma in Castilla-La Mancha, Spain. [PDF]

Open Respir Arch
Bujalance-Cabrera C, Espinosa de Los Monteros-Garde MJ, Morena-Vallés D, Godoy-Mayoral R, Bravo-Nieto JM, Jiménez-Arroyo M, Jiménez-López J, Lázaro-Polo FJ, Izquierdo-Alonso JL.   +8 more
europepmc   +1 more source

Targeting the Epithelial Alarmin Pathway with Tezepelumab in Highly Comorbid, Biologic-Experienced Severe Asthma: 52-Week Real-World Outcomes. [PDF]

J Clin Med
González-Pérez R, De Lorenzo-García I, Izaguirre-Flores H, González-Expósito H, García Gil S, Poza-Guedes P.   +5 more
europepmc   +1 more source

Tezepelumab in Adults with Uncontrolled Asthma

New England Journal of Medicine, 2019
openaire   +2 more sources

Effects of Tezepelumab in "United Airway Disease" (Asthma and CRSwNP). [PDF]

Case Rep Pulmonol
Lupia C, Piazzetta GL, Pastore D, Lobello N, Preianò M, Chiarella E, Maglio A, Vatrella A, Pelaia G, Pelaia C.   +9 more
europepmc   +1 more source

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma. [PDF]

Cureus
Fujimoto M, Yanagihara T, Sakaki Y, Fujita M.   +3 more
europepmc   +1 more source

Case Report: Tezepelumab as rescue therapy in near-fatal asthma requiring extracorporeal membrane oxygenation. [PDF]

Front Immunol
Oruqaj G, Bewersdorff J, Litzlbauer D, Wolff M, Sander M, Seeger W, Grimminger F, Hecker M, Tello K, Vadász I.   +9 more
europepmc   +1 more source

Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study. [PDF]

Respir Res
García-Rivero JL, Hannaoui Anaaoui A, Pallarés-Sanmartín A, Blanco-Aparicio M, García-Hernáez R, García-Gallardo Sanz V, Calvo-Álvarez U, Carazo-Fernández L, Hermida-Valverde T, Dorronsoro S, Carrascosa-Anguiano I, Lobato Astiárraga I, de Los Santos I, Enríquez-Rodríguez AI, Perez de Llano L, Álvarez Vega P, Abascal-Bolado B, Santibañez M.   +17 more
europepmc   +1 more source

Real-World Effectiveness of Tezepelumab in Severe Asthma: A Comparative Analysis of High and Low T2 Phenotypes. [PDF]

J Pers Med
Chiner E, Boira I, Antón M, Bernabeu MÁ, Cuevas C, Fernández P, Esteban V, Llombart M.   +7 more
europepmc   +1 more source